Effect of short- and long-acting inhaled beta2-agonists on exhaled nitric oxide in asthmatic patients
Authors:
- Sa KharitonovSKSa Kharitonov
- Pj BarnesPBPj Barnes
Open Access
- 1 July 1997
- journal article
- clinical trial
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 10 (7) , 1483-1488
Abstract
Increased concentrations of exhaled nitric oxide (NO) occur in patients with asthma, and exhaled NO may be useful for assessing the effect of drug therapy on airway inflammation. Beta2-agonists have been proposed to have both proinflammatory and anti-inflammatory effects. We therefore assessed exhaled NO after beta2-agonists in asthmatic patients. Two randomized, double-blind, placebo-controlled studies were conducted. Firstly, exhaled NO was measured in 18 asthmatics (9 taking inhaled glucocorticosteroids (GCS)) before and after nebulized salbutamol (5 mg), or identical placebo (0.9% saline). Exhaled NO and forced expiratory volume in one second (FEV1) were measured at 15 min intervals for 1 h (Study 1). Secondly, the effect of 1 week of treatment with the long-acting beta2-agonist, salmeterol (50 microg b.i.d.), added to either budesonide (800 microg b.i.d.) or placebo, was studied in eight mild asthmatic subjects (Study 2). Exhaled NO was measured by a chemiluminescence analyser, adapted for on-line recording. In Study 1, exhaled NO showed no significant change at any time-point in patients not taking inhaled GCS. In asthmatics on inhaled GCS, exhaled NO increased compared to placebo at 15 and 30 min, but this did not reach statistical significance. In Study 2, treatment with salmeterol increased FEV1, but exhaled NO levels were not significantly changed, either after budesonide treatment (143+/-35 to 179+/-67 ppb), or after placebo (201+/-68 to 211+/-65 ppb). Our results confirm that single high dose salbutamol does not increase exhaled nitric oxide in asthmatics not taking inhaled glucocorticosteroids. Salbutamol may increase exhaled nitric oxide in asthmatics taking inhaled glucocorticosteroids. However, regular use of salmeterol resulted in no change in exhaled nitric oxide, either used alone or in combination with inhaled glucocorticosteroids.Keywords
This publication has 16 references indexed in Scilit:
- Measurement of Exhaled Nitric Oxide by Three Different TechniquesAmerican Journal of Respiratory and Critical Care Medicine, 1996
- CONTROVERSIES INVOLVING INHALED β-AGONISTS AND INHALED CORTICOSTEROIDS IN THE TREATMENT OF ASTHMAClinics in Chest Medicine, 1995
- Interaction of Inhaled Beta 2 Agonist and Inhaled Corticosteroid on Airway Responsiveness to Allergen and MethacholineAmerican Journal of Respiratory and Critical Care Medicine, 1995
- Effect of a Nitric Oxide Synthase Inhibitor and a Glucocorticosteroid on Exhaled Nitric OxideAmerican Journal of Respiratory and Critical Care Medicine, 1995
- Expired Nitric Oxide Levels During Treatment of Acute AsthmaAmerican Journal of Respiratory and Critical Care Medicine, 1995
- Induction of nitric oxide synthase in asthmaThe Lancet, 1993
- Measurement of exhaled nitric oxide in man.Thorax, 1993
- Nitric oxide and lung disease.Thorax, 1993
- Regular inhaled beta-agonist treatment in bronchial asthmaThe Lancet, 1990
- Inhibition of IgE‐dependent histamine release from human dispersed lung mast cells by anti‐allergic drugs and salbutamolBritish Journal of Pharmacology, 1987